Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Georgia Tech Research Corp.

Division of Georgia Institute of Technology
www.gtrc.gatech.edu

Latest From Pharmachemie BV

Biopharma Quarterly Statistics Q1 2010

In Vivo presents another quarterly review of pharmaceutical/biotechnology dealmaking - for the first quarter of 2010. Our data come from Elsevier's Strategic Transactions. During the first quarter of 2010, biopharma companies raised $2.6 billion through 94 transactions, slightly better than last year's opening, but a decrease of 43% from Q4 2009. Early venture capital rounds were the most popular type of financings, followed closely by follow-on public offerings and private investments in public companies, but FOPOs clearly brought in the most money, $1.1 billion.With less than half the M&A deal volume of the previous quarter - however, about the same dollar figure - Q1 2010's 12 transactions brought in $7.1 billion.
BioPharmaceutical

Teva's Growth Momentum

Teva has built a successful generics business by being nimble, aggressive and opportunistic, and is betting heavily that by dominating global markets it can prosper even after the end of the current spate of patent expirations. The success of its innovative drug Copaxone has given it a hedge against the volatility of generics and also changed the company in many ways. While Teva has to balance two very different businesses with limited synergies, it also must come up with a viable successor to Copaxone in order to secure its foothold in proprietary pharmaceuticals while continuing its investment in generics.
BioPharmaceutical Strategy

Drug Franchises

Franchises can create scale for large and mid-sized drug companies alike. But few firms have really created these customer-driven alternatives to size-for-size's sake. Franchises need to be built up from an understanding of and relationships with the complex set of customers and suppliers in a particular field of specialization and should only be built where such a customer group truly exists.
BioPharmaceutical Strategy

The New Deal Structures: The Recipe is Creativity

With capital markets depressed and internal R&D growing ever more expensive, biotech and Big Pharma need each other more than ever. But a new wave of skeptical drug partners are forcing humbled biotechs to write deals that minimize risk without driving down the deal's value.
BioPharmaceutical Strategy
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register